Standard BioTools (LAB) AI Stock Analysis

• Market Cap: $407.64M
• Dividend Yield: N/A
• Average Volume (3M): 1.50M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.59
• Revenue Growth: -17.37%
• EPS Growth: 52.28%
• Country: US
• Employees: 814
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.04
• Shares Outstanding: 384,565,400
• 10 Day Avg. Volume: 2,361,187
• 30 Day Avg. Volume: 1,503,541
• PEG Ratio: 0.11
• Price to Book (P/B): 1.15
• Price to Sales (P/S): 5.72
• P/FCF Ratio: -5.91
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 3.82
• Enterprise Value/Gross Profit: 7.66
• Enterprise Value/Ebitda: -3.81
• 1Y Price Target: $1.35
• Price Target Upside: -4.26% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.12
• Revenue Forecast (FY): $79.73M

• Rating: 44 Neutral
• Price Target: $1.00 ▼(-29.08% Downside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

The score is held down primarily by weak financial performance (volatile/declining revenue, large ongoing losses, and persistent negative free cash flow) and bearish technical signals (price below key moving averages with negative MACD). Corporate events modestly improve the outlook via increased cash and operational streamlining, but valuation support is limited because losses make P/E less informative and there is no dividend yield.

Positive Factors

Proceeds from SomaLogic divestiture

Closing the SomaLogic divestiture materially strengthened liquidity and strategic optionality. The proceeds and royalty streams reduce near-term solvency pressure, fund disciplined M&A or R&D, and provide a multi-month to multi-quarter runway to execute cost restructuring toward adjusted EBITDA improvement.

Low financial leverage

Very low reported debt-to-equity gives the company durable financial flexibility, lowering interest burden and refinancing risk. Combined with divestiture cash, manageable leverage supports execution of strategic initiatives and reduces near-term solvency risk during the multi-quarter transition to positive adjusted results.

Stable gross margins

Consistent gross margins indicate intact product economics for instruments and consumables. That structural margin resilience means revenue recovery or scale gains can more directly translate to operating leverage and profitability if fixed costs remain controlled, supporting sustainable margin improvement over quarters.

Negative Factors

Persistent cash burn

Consistent negative operating and free cash flow signals the business cannot fund operations internally. Even with one-time divestiture proceeds, continued cash burn requires either sustained margin recovery, recurring revenue growth, or external financing; absent that, liquidity and capital structure could re-emerge as constraints.

Volatile and declining revenue

A large recent revenue drop undermines operating leverage and makes fixed-cost absorption harder. Revenue volatility also complicates forecasting, weakens recurring consumables sales, and lengthens the timeline to sustainably convert stable gross margins into positive operating profit and free cash flow.

Deep, persistent net losses

Very large negative net margins reflect structural unprofitability despite stable gross margins. This scale of losses requires either material revenue recovery or significant ongoing cost reduction to reach break-even, and reduces the company's ability to produce shareholder returns during the medium-term recovery window.

Standard BioTools Business Overview & Revenue Model

Company Description

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.

How the Company Makes Money

Standard BioTools generates revenue through the sale of its proprietary instruments, consumables, and software solutions. Key revenue streams include direct sales of lab equipment, such as the company's flagship products for single-cell analysis and multi-omics applications, as well as ongoing sales of consumable reagents required for these systems. The company also benefits from service contracts and maintenance agreements for its instruments. Additionally, Standard BioTools has established strategic partnerships with academic institutions, pharmaceutical companies, and research organizations, which can lead to collaborative projects, joint ventures, and potentially lucrative licensing agreements that further bolster its earnings.

Standard BioTools Financial Statement Overview

Summary

Overall financial quality is weak: revenue has been volatile with a sharp recent decline, the company remains deeply unprofitable with large operating losses, and free cash flow is consistently negative indicating ongoing cash burn and reliance on external funding. The main offset is a cleaner, low-leverage balance sheet in the most recent periods, which reduces near-term solvency risk but does not solve the profitability and cash flow issues.

Income Statement

Revenue has been volatile and recently weakened sharply (2025 revenue down ~34% year over year after a strong 2024), which is a key concern for operating leverage. Gross margin has held relatively steady around ~47–50% in recent years, showing the core product economics are intact. However, the company remains deeply unprofitable: net margins are consistently negative (roughly -70% to -190% historically, ~-88% in 2025), and operating losses remain large, signaling an unfinished path to scale and cost structure pressures.

Balance Sheet

Leverage appears manageable on the most recent balance sheet, with low debt relative to equity in 2024–2025 (debt-to-equity ~0.07), which reduces near-term solvency risk. That said, profitability is still negative, and equity has been unstable historically (negative equity in 2022–2023), indicating prior accumulated losses and balance-sheet volatility. Returns on equity are negative in the latest years, reinforcing that the balance sheet is not yet generating shareholder returns despite improved capitalization.

Cash Flow

Cash burn is the dominant issue: operating cash flow and free cash flow are consistently negative across all years provided, including 2025 (operating cash flow about -$74M; free cash flow about -$83M). While cash burn improved versus 2024, free cash flow still deteriorated year over year in 2025, and the business has not demonstrated an ability to fund operations internally. Overall, the cash flow profile implies continued dependence on external financing or further cost reductions to reach sustainability.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	85.33M	174.43M	106.34M	97.95M	130.58M
Gross Profit	42.54M	84.26M	50.45M	37.05M	69.37M
EBITDA	-94.96M	-118.14M	-54.46M	-173.57M	-44.27M
Net Income	-74.90M	-138.88M	-74.66M	-190.10M	-59.24M
Balance Sheet
Total Assets	567.75M	612.34M	323.07M	390.31M	275.21M
Cash, Cash Equivalents and Short-Term Investments	187.57M	292.87M	114.89M	165.78M	28.45M
Total Debt	30.83M	33.00M	98.21M	102.66M	111.65M
Total Liabilities	143.46M	140.62M	471.12M	471.78M	180.62M
Stockholders Equity	424.29M	471.72M	-148.05M	-81.47M	94.60M
Cash Flow
Free Cash Flow	-82.65M	-151.81M	-46.12M	-93.19M	-57.33M
Operating Cash Flow	-74.35M	-143.45M	-43.29M	-89.37M	-44.06M
Investing Cash Flow	24.77M	363.17M	20.24M	-88.13M	-11.95M
Financing Cash Flow	570.00K	-102.62M	-6.81M	230.76M	15.96M

Standard BioTools Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Negative. The current price of 1.41 is above the 20-day moving average (MA) of 1.16, above the 50-day MA of 1.34, and above the 200-day MA of 1.29, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 31.90 is Neutral, neither overbought nor oversold. The STOCH value of 10.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LAB.

Standard BioTools Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CSTL	60 Neutral	$819.69M	-46.67	-5.21%	―	10.15%	-295.52%
CDNA	56 Neutral	$962.87M	-47.01	24.11%	―	14.46%	―
PSNL	53 Neutral	$907.16M	-8.74	-35.02%	―	-21.02%	47.74%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FLGT	49 Neutral	$430.67M	-13.36	-5.39%	―	13.60%	74.64%
MYGN	48 Neutral	$494.66M	-1.57	-68.45%	―	0.21%	-233.51%
LAB	44 Neutral	$407.64M	-6.52	-13.73%	―	-17.37%	52.28%

Standard BioTools Corporate Events

Standard BioTools Details SomaLogic Sale and Profitability Path

Standard BioTools reported fourth-quarter 2025 revenue from continuing operations of $23.8 million and full-year revenue of $85.3 million, declines of 4% and 6% respectively, driven by weaker consumables and services demand amid funding and capital constraints, partly offset by growth in imaging instruments. Despite an annual net loss of $58.8 million, improved gross margins, lower operating expenses from restructuring, a tax-related swing to fourth-quarter net income, and roughly $550 million in cash and investments following the January 30, 2026 SomaLogic sale leave the company pursuing a path to profitability and inorganic growth, supported by about $1 billion in U.S. NOL carryforwards and a 2026 revenue outlook of $80 million to $85 million from continuing operations.

The most recent analyst rating on (LAB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard BioTools Completes Major Proteomics Business Divestiture

On January 30, 2026, Standard BioTools completed the sale of its aptamer-based and functional proteomics business, including SomaLogic and Sengenics entities and the SomaScan, KREX and Single SOMAmer assay franchises, to Illumina for $350 million in upfront cash and up to $75 million in performance-based earnout payments, for total potential proceeds of $425 million plus specified royalties. The divestiture, which leaves Standard BioTools retaining its mass cytometry and microfluidics operations, also gives the company 10-year royalty streams on SOMAmer-based NGS library preparation kits and Single SOMAmer sales and a co-exclusive license to Single SOMAmer IP, and has boosted its estimated cash and cash equivalents to about $550 million at closing, positioning the company to pursue inorganic growth and move its streamlined continuing operations toward positive adjusted EBITDA in 2026, while ending its direct economic participation in the prior SomaLogic-Illumina collaboration.

The most recent analyst rating on (LAB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.